2024
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
Greenman M, Bellone S, Demirkiran C, Hartwich T, Santin A. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecologic Oncology Reports 2024, 54: 101459. PMID: 39108617, PMCID: PMC11300917, DOI: 10.1016/j.gore.2024.101459.Peer-Reviewed Original ResearchHigh grade serous ovarian cancerAntibody-drug conjugatesSerous ovarian cancerSacituzumab govitecanOvarian cancerTreatment optionsPlatinum-resistant ovarian cancer patientsDose-limiting toxicityOvarian cancer patientsNovel treatment optionsPartial responseRecurrent diseaseDose reductionCancer patientsClinical trialsBackground treatmentTargeted treatmentChemotherapyTreatmentCancerDoseDiseaseOptionsTrop2Patients
2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.Peer-Reviewed Original ResearchUterine serous carcinomaHER2/neuSerous carcinomaT-DXdTreatment optionsRecurrent uterine serous carcinomaDose-limiting side effectEffective treatment optionNew treatment optionsBone painRecurrent diseaseDurable responsesTrastuzumab deruxtecanCA 125Disease burdenSide effectsCarcinomaAntibody drugsTreatmentSignificant reductionDiseaseNeuExperimental treatmentsMetastaticPainPembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.Peer-Reviewed Original ResearchConceptsUse of pembrolizumabCervical cancerStandard chemotherapyMetastatic PD-L1Recurrent cervical cancerMetastatic cervical cancerNon-expressing tumorsVEGF therapyPD-L1Clinical efficacyGlobal morbidityPharmacologic propertiesChemotherapyPembrolizumabBevacizumabCancerRecurrentTreatmentTolerabilityFurther benefitImmunotherapyContraindicationsMorbidityEvidencePatients
2022
Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Smith A, Keefe S, Bird S, Dutta L, Orlowski R, Lorusso D. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Obstetrical & Gynecological Survey 2022, 77: 275-276. DOI: 10.1097/ogx.0000000000001032.Peer-Reviewed Original ResearchEndometrial cancerRecurrent endometrial cancerSecond-line treatmentAdvanced endometrial cancerPlatinum-based chemotherapyRecurrent endometrial carcinomaTyrosine kinase inhibitorsEndometrial carcinomaOptimal treatmentDisease progressionLimited efficacySingle agentKinase inhibitorsLenvatinibCancerTreatmentPembrolizumabLittle consensusChemotherapyCarcinomaProgression
2021
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.Peer-Reviewed Original ResearchEpithelial ovarian cancerOvarian cancerClinical dataEpithelial ovarian cancer treatmentTaxane-treated patientsUse of ixabepiloneRefractory ovarian cancerOngoing clinical trialsStandard of careOvarian cancer treatmentClinical trialsRecurrent treatmentTaxane resistanceCurrent standard practiceChemotherapeutic agentsTherapeutic agentsCancerCancer treatmentPutative mechanismsMicrotubular functionTreatmentDrugs partTaxanesCell deathCurrent useVessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment
Liu F, Wu H, Peng B, Zhang S, Ma J, Deng G, Zou P, Liu J, Chen AT, Li D, Bellone S, Santin AD, Moliterno J, Zhou J. Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment. Nano Letters 2021, 21: 8111-8118. PMID: 34597054, DOI: 10.1021/acs.nanolett.1c02459.Peer-Reviewed Original ResearchConceptsBrain cancer treatmentSystemic chemotherapyCancer treatmentBrain cancer developmentNoninvasive deliverySystemic drug deliveryIntravenous administrationBrain tumorsIntracranial injectionBrain cancerTumor vasculatureCancer developmentImproved efficacyTumor cellsImproved treatmentMagnetic field exposureChemotherapyClinical applicationTumorsNoninvasive natureTreatmentDeliveryHyperthermiaField exposureCancerIvermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Santin A, Scheim D, McCullough P, Yagisawa M, Borody T. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes And New Infections 2021, 43: 100924. PMID: 34466270, PMCID: PMC8383101, DOI: 10.1016/j.nmni.2021.100924.Peer-Reviewed Original ResearchMultifaceted drugSARS-CoV-2 spike proteinCOVID-19SARS-CoV-2Such inpatientsOutpatient treatmentClinical trialsDevastating tropical diseasesGlobal scourgeRelative riskCOVID-19 fatalitiesIVM treatmentTreatment RCTsAnimal modelsExcess deathsFull efficacyInfectious diseasesTropical diseasesSpike proteinIvermectinTreatmentDiseaseBiological mechanismsDrugsDeath
2019
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatment
2015
An update on the current pharmacotherapy for endometrial cancer
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.Peer-Reviewed Original ResearchConceptsEndometrial cancerMainstay of treatmentCommon gynecologic malignancyCurrent conventional therapiesGynecologic malignanciesCurrent pharmacotherapyAvailable pharmacotherapiesConventional therapyCurrent therapiesEndometrial tumorsTargeted therapyImmunohistochemical characterizationRadiation therapyClinical careAggressive formNew therapiesPreclinical settingTherapyTherapeutic agentsCancerPharmacotherapyTumorsAvailable literatureHistoric treatmentTreatmentClostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers
Black JD, Lopez S, Cocco E, Schwab CL, English DP, Santin AD. Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers. Toxins 2015, 7: 1116-1125. PMID: 25835384, PMCID: PMC4417958, DOI: 10.3390/toxins7041116.Peer-Reviewed Original ResearchConceptsClostridium perfringens enterotoxinClaudin-3Claudin-4Perfringens enterotoxinAggressive human cancer cellsGynecologic malignanciesGynecologic cancerHuman cancer cellsOperative settingHuman tumorsCancer cellsPotential roleTumorsSurface proteinsEnterotoxinTreatmentHigh affinitySurgeryMalignancyCancerCytolysisReceptors
2014
Taxanes
Schwab CL, English DP, Roque DM, Santin AD. Taxanes. Anti-Cancer Drugs 2014, 25: 522-535. PMID: 24300913, PMCID: PMC3980024, DOI: 10.1097/cad.0000000000000057.Peer-Reviewed Original ResearchConceptsTaxane-based chemotherapyUse of taxanesGynecologic cancerRoute of treatmentRadiation sensitizing propertiesGynecologic malignanciesCervical cancerEffective therapyTreatment intervalAppropriate doseResponse rateNew treatmentsChemotherapeutic agentsTaxanesCancerSensitizing propertiesChemotherapyTreatmentActive agentsMalignancyDocetaxelOvarianTherapyAgentsDose
2012
EGFR/HER-targeted therapeutics in ovarian cancer
Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry 2012, 4: 447-469. PMID: 22416774, PMCID: PMC4620931, DOI: 10.4155/fmc.12.11.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerHuman epidermal growth factor receptor (HER) familyEpidermal growth factor receptor familyGrowth factor receptor familyTreatment modalitiesFactor receptor familyClinical developmentDiverse malignanciesEGFR/Clinical settingUS FDACancerNew drugsReceptor familyPatientsMalignancyTherapeuticsTreatmentTyrosine kinaseSurvivalSame periodCarcinomaMajor roleEtiology